A growing body of research is revealing new potential benefits for a popular class of diabetes and weight-loss medications. For millions of Americans living with both type 2 diabetes and a common liver condition called steatotic liver disease, these drugs may offer more than blood sugar control.

According to a new study published in the American Journal of Gastroenterology, adults with diabetes and steatotic liver disease who started taking a GLP-1 receptor agonist had a 38% to 42% lower risk of experiencing serious liver-related events over nearly three years of follow-up. The research drew data from the National Institutes of Health’s All of Us research program, which tracks health information from a diverse group of participants across the United States.

This finding is particularly important because steatotic liver disease—formerly known as nonalcoholic fatty liver disease—affects about one in three American adults. When combined with diabetes, the risk of liver damage increases significantly.

What This Means for Your Health

If you or a loved one has type 2 diabetes and has been told you have a fatty liver, these results suggest that GLP-1 medications might offer a double benefit. These drugs, which include well-known brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, work by mimicking a natural hormone that helps regulate blood sugar and appetite.

Experts in liver disease caution, however, that these findings are observational, meaning they show a link but do not prove cause and effect. Patients should not start or stop any medication without discussing it with their healthcare provider. The study’s lead researchers emphasized that more clinical trials are needed to confirm whether GLP-1 drugs directly protect the liver or if the benefit comes from the weight loss and blood sugar improvements these medications produce.

Better Scanning for Liver Cancer in Cirrhosis Patients

For patients with cirrhosis—scarring of the liver—regular screening for liver cancer is a critical part of care. A new study in Hepatology suggests that a faster, simpler MRI technique could dramatically improve detection rates.

Researchers tested a rapid abbreviated non-contrast MRI protocol, which does not require injecting dye into the bloodstream. This approach found liver cancer with 94.6% sensitivity, compared to just 51.4% for standard ultrasound. The MRI method also had higher specificity (96.6% versus 69.5%), meaning it was far less likely to produce false alarms.

For patients, this could mean fewer unnecessary follow-up tests and greater peace of mind. However, the study was conducted at a single medical center, and experts note that MRI is more expensive and less widely available than ultrasound. Still, for high-risk patients, this abbreviated MRI approach could become a valuable screening tool.

Frailty and Hospital Risk in Liver Disease

Doctors have long known that patients with cirrhosis are at high risk for hospitalization. Now, a study in Clinical Gastroenterology and Hepatology identifies specific measures that can predict which patients are most likely to need hospital care.

Researchers found that simple tests of frailty and functional capacity—such as how fast a patient can walk or how easily they can rise from a chair—can forecast future hospitalization. This is important because it gives doctors a practical, low-cost way to identify patients who might benefit from extra support or closer monitoring.

For patients and families, this research underscores the importance of staying physically active and maintaining strength, even when living with a chronic liver condition. Simple exercises and physical therapy may help reduce the risk of hospital stays.

Rural Communities Face Higher Liver Cancer Burden

A study published in JAMA Network Open examined the gap in liver cancer rates between rural and urban areas in the United States. The findings highlight a troubling disparity: people living in rural communities face higher rates of hepatocellular carcinoma (HCC), the most common type of liver cancer, as well as higher death rates from the disease.

Several factors likely contribute to this gap. Rural residents often have less access to specialty care, including liver specialists and advanced cancer treatments. They may also have higher rates of hepatitis C infection, alcohol-related liver disease, and obesity—all risk factors for liver cancer.

Public health experts say this study points to the need for better screening programs and healthcare resources in rural America. Telemedicine, mobile health clinics, and community outreach could help bridge the gap.

Hepatitis D: Understanding Who Achieves Viral Suppression

Hepatitis D is a rare but serious liver infection that only occurs in people who already have hepatitis B. A study in Hepatology examined which patients with chronic hepatitis D are most likely to achieve spontaneous viral suppression—meaning the virus becomes undetectable without treatment.

Researchers found that spontaneous suppression was more common in men and in patients with diabetes. However, it was less likely in patients who started with higher levels of hepatitis D virus RNA, hepatitis B surface antigen, and a liver enzyme called alanine aminotransferase (ALT).

These findings help doctors identify which patients may need more aggressive treatment and which might be able to avoid or delay therapy. For patients, this means more personalized care based on their specific viral levels and health profile.

Liver Transplant Outcomes: Co-Infection Surprises

A 20-year analysis of liver transplant recipients, published in Clinical Gastroenterology and Hepatology, revealed an unexpected finding. Patients who had both hepatitis D and hepatitis B when they received a new liver had more advanced disease at the time of transplant and tended to be younger than patients with hepatitis B alone.

However, the co-infected group had higher survival rates after transplant. Experts believe this may be because hepatitis D can suppress hepatitis B replication, and because patients with co-infection often receive careful monitoring and antiviral therapy. For patients awaiting transplant, this information can help set realistic expectations about outcomes.

Children Avoiding Bathroom Use at School

A study in JAMA Network Open explored why Dutch children withhold bowel movements while at school. The top reasons cited were privacy concerns, hygiene issues, feelings of taboo, and shame.

This matters because regularly holding in stool can lead to constipation, abdominal pain, and long-term bowel problems. Pediatric gastroenterologists say the findings likely apply to children in many countries, including the United States.

Parents and schools can help by ensuring bathrooms are clean, private, and accessible. Teachers should allow students to use the restroom when needed without requiring elaborate explanations or permission slips.

New Treatment for Fecal Incontinence

A randomized trial published in Gastroenterology tested a therapy called translumbosacral neuromodulation for fecal incontinence—a condition that affects millions of people but is rarely discussed. The treatment involves mild electrical stimulation to nerves in the lower back and sacrum.

Researchers found the therapy was safe and provided significant improvement in bowel symptoms compared to a sham (fake) procedure. For patients who have not found relief with diet changes, medications, or pelvic floor therapy, this approach offers a new option.

Cruise Ship Norovirus Outbreaks

Norovirus, a highly contagious stomach bug, sickened 115 people aboard a Princess Cruises ship that recently traveled through the Caribbean, according to the CDC. In a separate incident, passengers unaffected by a norovirus outbreak on a British cruise ship were allowed to disembark in Bordeaux, France.

Norovirus spreads easily in close quarters like cruise ships, schools, and nursing homes. Symptoms include vomiting, diarrhea, and stomach cramps. The best prevention is frequent handwashing with soap and water—hand sanitizer is less effective against this virus.

FDA Approves New Drug for Rare Bile Duct Cancer

The FDA has approved zenocutuzumab, sold under the brand name Bizengri, for a specific type of bile duct cancer called cholangiocarcinoma. The drug is for patients with advanced, unresectable, or metastatic disease who have a rare genetic change called an NRG1 gene fusion.

While this cancer is uncommon, the approval represents an important step in precision medicine—treating patients based on the genetic makeup of their tumor rather than just the location of the cancer.

IBD Treatments Help Beyond the Gut

A systematic review and meta-analysis published in Inflammatory Bowel Diseases found that advanced therapies for inflammatory bowel disease (IBD) also improve skin and joint symptoms. Many people with Crohn’s disease or ulcerative colitis also experience arthritis, rashes, or other inflammatory problems outside the digestive tract.

For patients, this means that a single medication may address multiple symptoms. A separate U.K. analysis examined treatment choices for late-onset IBD, which occurs in older adults. Experts say treatment decisions for this group must consider other health conditions and medications common in older patients.

New Tool to Predict PSC Risk

A multicenter study in Clinical Gastroenterology and Hepatology validated a scoring system called HelPSCore for primary sclerosing cholangitis (PSC), a rare liver disease that causes bile duct damage. The time-dependent score helps identify high-risk patients who may need more aggressive monitoring or early referral for transplant.

For patients with PSC, this tool could mean more personalized care and better timing of interventions.

Practical Takeaways for Readers

• If you have diabetes and fatty liver disease: Ask your doctor whether a GLP-1 medication might be right for you.
• If you have cirrhosis: Stay active to maintain strength and reduce hospital risk. Ask about the best screening method for liver cancer.
• If you live in a rural area: Be aware of your higher risk for liver cancer and discuss screening with your doctor.
• If your child avoids school bathrooms: Talk to them about why and work with the school to improve bathroom conditions.
• If you have IBD: Know that treatments may help joint and skin symptoms too—discuss all your symptoms with your gastroenterologist.

Source: MedPage Today